Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin, type II cytoskeletal 2 oral (KRT76)
- Target
- KRT76
- Molecular classification
- Intermediate filament protein, Cytoskeletal protein, Type II keratin
01
Overview
Keratin, type II cytoskeletal 2 oral (KRT76) is a type II intermediate filament protein expressed largely in differentiated, suprabasal layers of stratified epithelia, including oral cavity, skin, and squamous stomach. KRT76 is essential for maintaining epithelial barrier integrity by regulating tight junction function, particularly through its interaction with Claudin 1; deficiency leads to skin barrier defects, impaired wound healing, hyperproliferation, and inflammation. Loss or downregulation of KRT76 is associated with certain inflammatory skin diseases such as psoriasis and correlates with poor prognosis in oral squamous cell carcinoma, suggesting a role in epithelial carcinogenesis and immune regulation. KRT76 is not currently considered a direct therapeutic target, and there are no known drugs that selectively interact with it. Its biological importance is highlighted in tissue homeostasis, cytokine regulation, and possibly in the modulation of antitumor immune responses.
- Other names
- Keratin 76KRT76Keratin, type II cytoskeletal 2 oralKRT2BKRT2PCK-2PK2PK76HUMCYT2ACytokeratin-2PType-II keratin Kb9keratin 2pcytokeratin 2cytokeratin-2P
02
Biological functions
Maintenance of epithelial barrier integrityWound healing in skin and oral mucosaRegulation of tight junction composition, especially Claudin 1 localizationRegulation of immune responses in epithelium
03
Disease associations
Cancer (notably oral squamous cell carcinoma)Chronic inflammation and barrier-related skin disorders (including psoriasis)
04
Biomarkers
Loss or downregulation may serve as a biomarker for poor prognosis in oral squamous cell carcinoma
Beyond the preview
Go deeper on Keratin, type II cytoskeletal 2 oral (KRT76).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Keratin, type II cytoskeletal 2 oral (KRT76).